Optimal outcomes in young class 3 patients with thalassemia undergoing HLA-identical sibling bone marrow transplantation

Transplantation

Volumn 100, Issue 4, 2016, Pages 925-932

  Gaziev, Javid ^a   Isgrò, Antonella ^a   Sodani, Pietro ^a   Marziali, Marco ^a   Paciaroni, Katia ^a   Gallucci, Cristiano ^a   De Angelis, Gioia ^a   Andreani, Marco ^a   Testi, Manuela ^a   Alfieri, Cecilia ^a   Ribersani, Michela ^a   Galluccio, Tiziana ^a   Battarra, Maria Rosa ^a   Morrone, Aldo ^a   Lucarelli, Guido ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; HYDROXYUREA; THIOTEPA; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENGRAFTMENT; ENTEROPATHY; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HLA MATCHING; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE INFECTION; INTESTINAL BLEEDING; LIVER DISEASE; LIVER VENOOCCLUSIVE DISEASE; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIBLING; SYSTEMIC MYCOSIS; THALASSEMIA; THROMBOCYTOPENIA; ADVERSE EFFECTS; AGE; COMBINATION DRUG THERAPY; GENETICS; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INCIDENCE; ITALY; KAPLAN MEIER METHOD; LIVING DONOR; PREDICTIVE VALUE; PRESCHOOL CHILD; PROCEDURES; RISK FACTOR; TIME FACTOR; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LIVING DONORS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; ROME; SIBLINGS; THALASSEMIA; TIME FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84944338667     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000928     Document Type: Article

References (46)

1. Piga A, Galanello R, Forni G, et al. Randomized phase II trial of deferasirox (Exjade, ICL 670), once daily, orally-administered iron chelator, in comparison to deferoximine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873-880.
2. Telfer P, Cohen PG, Christou S, et al. Survival of medically treated thalas-saemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica. 2006;91:1187-1192.
3. Management of birth defects and haemoglobin disorders. Report of a Joint WHO-March of Dimes Meeting. Geneva, Switzerland, 17-19. Available at:http://www.who.int/genomics/publications/WHO-MODreport-final.pdf. Published 2006. Accessed March 1, 2015.
4. Cunningham MJ, Macklin EA, Neueld EJ, et al. Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004;104:34-39.
5. Thomas ED, Buckner CD, Sanders JE, et al. Marrow transplantation for thalassaemia. Lancet. 1982;2:227-229.
6. Lucarelli G, Gaziev J. Advances in the allogeneic transplantation for thalas-semia. Blood Rev. 2008;22:53-63.
7. Di Bartolomeo P, Santarone S, Di Bartolomeo E, et al. Long-term results of survival in patients with thalassemia major treated with bone marrow transplantation. Am J Hematol. 2008;83:528-530.
8. Gaziev J, Lucarelli G. Allogeneic cellular gene therapy for hemoglobinopa-thies. Hematol Oncol Clin North Am. 2010;24:1145-1163.
9. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322:417-421.
10. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in thalassemia. Hematol Oncol Clin North Am. 1991;5:549-556.
11. Lucarelli G, Clift R, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood. 1996;87:2082-2088.
12. Lucarelli G, Andreani M, Angelucci E. The cure of thalassemia by bone marrow transplantation. Blood Rev. 2002;16:81-85.
13. Sodani P, Gaziev J, Polchi P, et al. New approach for bone marrow trans-plantationinpatients with class3thalassemia aged younger than17years. Blood. 2004;104:1201-1203.
14. Irfan M, Hashmi K, Adil S, et al. Beta-thalassaemia major: bone marrow versus peripheral blood stem cell transplantation. J Pak Med Assoc. 2008;58:107-110.
15. Chiesa R, Cappelli B, Crocchiolo R, et al. Unpredictability of intravenous busulfan pharmacokinetics in children undergoing hematopoietic stem cell transplantation for advanced beta thalassemia: limited toxicity with a dose-adjustment policy. Biol Blood Marrow Transplant. 2010;16: 622-628.
16. Gaziev J, Nguyen L, Puozzo C, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood. 2010;115:4597-4604.
17. Gaziev J, Isgrò A, Marziali M, et al. Higher CD3+ and CD34+ cell doses in the graft increase the incidence of GVHD in children receiving BMT for thalassemia. Bone Marrow Transplant. 2012;47:107-112.
18. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD. Bone Marrow Transplant. 1995;15:825-828.
19. Filipovich A, Weisdorf D, Pavletic S, et al. National Institute of health consensus development project on criteria for clinical trials in chronic graft versus-host disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2005;11:945-955.
20. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risk: new representation of old estimators. Stat Med. 1999;18:695-706.
22. Kanda Y. Investigation of the freely available easy-to use software 'EZR' for medical statistix. Bone Marrow Transplant. 2013;48:452-458.
23. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
24. Mathews V, Savani BN. Conditioning regimens in allo-SCT for thalassemia major. Bone Marrow Transplant. 2014;49:607-610.
25. Sabloff M, Chandy M, Wang Z, et al. HLA-matched sibling bone marrow transplantation for ß-thalassemia major. Blood. 2011;117:1745-1750.
26. Mathews V, George B, Viswabandya A, et al. Improved clinical outcomes of high risk ß thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. Plos One. 2013;8:e61637.
27. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 2003;9:519-528.
28. Horan JT, Liesveld JL, Fenton P et al. Hematopoietic stem cell transplantation after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant. 2005;35:171-177.
29. Hongeng S, Pakakasama S, Chuansumrit A, et al. Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients. Am J Hematol. 2007;82:1095-1098.
30. Choundhary D, Sharma SK, Gupta N, et al. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from North India. Biol Blood Marrow Transplant. 2013;19:492-503.
31. Bernardo ME, Piras E, Vacca A, et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood. 2012;120:473-476.
32. Anurathapan U, Pakakasama S, Rujkijyanont P et al. Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: safe approach to disease control. Biol Blood Marrow Transplant. 2013;19:1254-1262.
33. Valcarcel D, Martino R, Caballero D, et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2003;31:387-392.
34. Salit RB, Fowler DH, Dean RM, et al. Host lymphocyte depletion as a strat egy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:1509-1513.
35. Carvallo C, Geller N, Kurlander R, et al. Prior chemotherapy and allograft CD34∗ dose impact donor engraftment following non-myeloablative allogeneic stem cell transplantation in patients with solid tumors. Blood. 2004;103:1560-1563.
36. Down JD, Westerhof GR, Boudewijn A, et al. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice. Bone Marrow Transplant. 1998;21:327-330.
37. Rosales F, Peylan-Ramu N, Cividalli G, et al. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases. Bone Marrow Transplant. 1999;23:861-865.
38. Aversa F, Terenzi A, Carotti A, et al. Improved outcome with T-cell depleted bone marrow transplantation for acute leukemia. J Clin Oncol. 1999;17: 1545-1550.
39. Parikh SH, Mendizabal A, Benjamin CL, et al. A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with non-malignant diseases. Biol Blood Marrow Transplant. 2014;20:326-336.
40. Biral E, Cappelli B, Zugna D, et al. Intensified immunosuppression with ATG reduces graft failure without affecting immune reconstitution or infections in high risk beta thalassemia patients after HLA-identical sibling HSCT. Bone Marrow Transplant. 2010;45:S1-S45.
41. Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phaseIIstudy from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2013;18: 1265-1272.
42. La Nasa G, Argiolu F, Giardini C, et al. Unrelated donor bone marrow transplantation for thalassemia patients. The experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci. 2005;1054:186-195.
43. Chandy M, Mathews V, George B, et al. Reduced intensity conditioning (RIC) with fludarabine, busulfan and cyclophosphamide for high risk patients with thalassemia major undergoing allogeneic bone marrow transplantation results in high rejection rates. Blood. 2007; 110:1998.
44. Yesilipek MA, Ertem M, Cetin M, et al. HLA-matched family hematopoietic stem cell transplantationinchildren with beta thalassemia major: the experience of the Turkish Pediatric Bone Marrow Transplantation Group. Pediatr Transplant. 2012;16:846-851.
45. Iravani M, Tavakoli E, Bbaie MH, et al. Comparision of peripheral stem cell transplant with bone marrow transplant in class 3 thalassemic patients. Exp Clin Transplant. 2010;8:66-73.
46. Hussein AA, Al-Zaben A, Ghatasheh L, et al. Risk adopted allogeneic he-matopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major. Pediatr Blood Cancer. 2013;60: 345-1349.